Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS)

Clinical Infectious Diseases(2022)10.1093/cid/ciac103Source: DataRank Database

Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS) is a dataset published in Clinical Infectious Diseases (2022). On theSindex it has a DataRank of 3.7, placing it in the top 6.1% of the data-sharing corpus. It has been cited 115 times, with 93 citing works in its 1-hop citation network.

Top 6%percentile

3.7DataRank

Ranks in the top 6% for downstream scientific impact

Data paper Open Access115 citations · 93 citing works in its network

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 10.72)OA: bronzeTopics (56)Linked Datasets (14)DataCite Reuse (14)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (3)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (1/3)

Dataset classification

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 19%Citation Network 81%

Base Score Contribution

0.713

From this paper's citation signal

Citation Network Contribution

3.0

From 78 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 93 citers.

Safety, tolerability, and pharmacokinetics of half-life extended SARS-CoV-2–neutralizing monoclonal antibodies AZD7442 (tixagevimab/cilgavimab) in healthy Japanese adults
Journal of Infection and Chemotherapy202313 citations14 referencesContributes 0.189
Impact of Seasonal Coronavirus Antibodies on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Responses in Solid Organ Transplant Recipients
Clinical Infectious Diseases20225 citations15 referencesContributes 0.119
Epitope Mapping of SARS-CoV-2 Spike Antibodies in Vaccinated Kidney Transplant Recipients Reveals Poor Spike Coverage Compared to Healthy Controls
The Journal of Infectious Diseases20235 citations15 referencesContributes 0.119
Rapid Wane and Recovery of XBB Sublineage Neutralization After Sequential Omicron-based Vaccination in Solid Organ Transplant Recipients
Clinical Infectious Diseases20243 citations12 referencesContributes 0.116
Uptake of COVID-19 vaccination in people with blood cancer: Population-level cohort study of 12 million patients in England
European Journal of Cancer202320 citations28 referencesContributes 0.109

Authors (42)

Mounzer Agha ORCID,Andrew Bilderback ORCID,Amy Lukanski ORCID,Kelsey Linstrum,Rachel Troyan

Live enrichment

PubMed:35179197 PMC:PMC8903515 OpenAlex:https://openalex.org/W4210317504

National Institutes of Health

Grant: K23AI154546

NCI NIH HHS

Grant: P30 CA047904

National Institutes of Health

Grant: 1K23AI154546-01A1

The Gut Microbiome in Carbapenem-Resistant Enterobacteriaceae Colonization, Persistence, Infection, and Tolerance after Lung or Liver Transplantation

FWCI

10.72

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

bronzeLicense: OUP Standard Publication Reuse

journalhttps://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciac103/43918660/ciac103.pdf

publisherhttps://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciac103/43918660/ciac103.pdf

publisherhttps://academic.oup.com/cid/article-pdf/75/1/e630/45513655/ciac103.pdf

journalhttps://doi.org/10.1093/cid/ciac103

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35179197

Fields of Study

SARS-CoV-2 and COVID-19 ResearchCOVID-19 and healthcare impactsCOVID-19 Clinical Research Studies0303 health sciences03 medical and health sciencesAdultAntibodies, ViralBNT162 VaccineCOVID-19COVID-19 VaccinesHIV InfectionsHumansImmunocompromised HostProspective StudiesSARS-CoV-2Vaccination

MeSH Terms

COVID-19SARS-CoV-2COVID-19 VaccinesBNT162 VaccineAdultAntibodies, ViralHumansProspective StudiesVaccinationHIV InfectionsImmunocompromised Host

Keywords

Coronavirus disease 2019 (COVID-19)Medicine2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VaccinationVirologyCoronavirusBroad spectrumCoronavirus InfectionsBetacoronavirusImmunologyDiseaseOutbreakInfectious disease (medical specialty)Internal medicineImmunocompromisedSars-cov-2 AntibodyCovid-19 VaccinesSars-cov-2 NeutralizationAdultSARS-CoV-2COVID-19HIV InfectionsAntibodies, ViralImmunocompromised HostMajor ArticleHumansProspective StudiesBNT162 Vaccine

Sustainable Development Goals

SDG 3: 3. Good healthSDG 16: 16. Peace & justiceSDG 0: Good health and well-being

Additional file 1 of Uptake, effectiveness and safety of COVID-19 vaccines in individuals at clinical risk due to immunosuppressive drug therapy or transplantation procedures: a population-based cohort study in England

10.6084/m9.figshare.26011757.v1figshare

10.6084/m9.figshare.26011757figshare

Additional file 2 of Uptake, effectiveness and safety of COVID-19 vaccines in individuals at clinical risk due to immunosuppressive drug therapy or transplantation procedures: a population-based cohort study in England

10.6084/m9.figshare.26011965.v1figshare

10.6084/m9.figshare.26011965figshare

Additional file 1 of Risk of breakthrough infection and hospitalisation after COVID-19 primary vaccination by HIV status in four Italian regions during 2021

10.6084/m9.figshare.26019581.v1figshare

Additional file 1 of Risk of breakthrough infection and hospitalisation after COVID-19 primary vaccination by HIV status in four Italian regions during 2021

10.6084/m9.figshare.26019581figshare

Additional file 3 of Uptake, effectiveness and safety of COVID-19 vaccines in individuals at clinical risk due to immunosuppressive drug therapy or transplantation procedures: a population-based cohort study in England

10.6084/m9.figshare.26732011.v1figshare

10.6084/m9.figshare.26732011figshare

Additional file 4 of Uptake, effectiveness and safety of COVID-19 vaccines in individuals at clinical risk due to immunosuppressive drug therapy or transplantation procedures: a population-based cohort study in England

10.6084/m9.figshare.26732017.v1figshare

10.6084/m9.figshare.26732017figshare

Additional file 5 of Uptake, effectiveness and safety of COVID-19 vaccines in individuals at clinical risk due to immunosuppressive drug therapy or transplantation procedures: a population-based cohort study in England

10.6084/m9.figshare.26732020.v1figshare

10.6084/m9.figshare.26732020figshare

Additional file 6 of Uptake, effectiveness and safety of COVID-19 vaccines in individuals at clinical risk due to immunosuppressive drug therapy or transplantation procedures: a population-based cohort study in England

10.6084/m9.figshare.26732023.v1figshare

10.6084/m9.figshare.26732023figshare